CERO (CERo Therapeutics Holdings) YoY EBITDA Growth: 99.99% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings YoY EBITDA Growth?

CERo Therapeutics Holdings CERO +3.77% YoY EBITDA Growth is 99.99% as of Jun. 2026. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CERo Therapeutics Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 99.99%.

CERo Therapeutics Holdings's EBITDA per Share for the three months ended in Jun. 2026 was $-0.00.

CERo Therapeutics Holdings YoY EBITDA Growth Related Terms

CERo Therapeutics Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings YoY EBITDA Growth Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -0.16 49.85 100.00 0.00

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.36 98.16 0.00 99.33 99.99

CERo Therapeutics Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CERo Therapeutics Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-4.312-0)/ | 0 |
=N/A %

CERo Therapeutics Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.001--10.553)/ | -10.553 |
=99.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 99.99% mean?
CERo Therapeutics Holdings (CERO) has a YoY EBITDA Growth of 99.99% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for CERo Therapeutics Holdings and its competitors.
Is CERo Therapeutics Holdings' YoY EBITDA Growth too high?
CERo Therapeutics Holdings' current YoY EBITDA Growth is 99.99%.
How does CERo Therapeutics Holdings' YoY EBITDA Growth compare to AGTX and ZVSA?
CERo Therapeutics Holdings' YoY EBITDA Growth of 99.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current YoY EBITDA Growth is 99.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current YoY EBITDA Growth of 99.99%. The current YoY EBITDA Growth is 99.99%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current YoY EBITDA Growth is 99.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.